全文获取类型
收费全文 | 18868篇 |
免费 | 1187篇 |
国内免费 | 84篇 |
专业分类
耳鼻咽喉 | 181篇 |
儿科学 | 599篇 |
妇产科学 | 421篇 |
基础医学 | 2539篇 |
口腔科学 | 373篇 |
临床医学 | 2188篇 |
内科学 | 4437篇 |
皮肤病学 | 527篇 |
神经病学 | 1896篇 |
特种医学 | 412篇 |
外科学 | 1453篇 |
综合类 | 101篇 |
一般理论 | 8篇 |
预防医学 | 1932篇 |
眼科学 | 306篇 |
药学 | 1277篇 |
中国医学 | 69篇 |
肿瘤学 | 1420篇 |
出版年
2023年 | 152篇 |
2022年 | 270篇 |
2021年 | 544篇 |
2020年 | 329篇 |
2019年 | 525篇 |
2018年 | 643篇 |
2017年 | 402篇 |
2016年 | 484篇 |
2015年 | 550篇 |
2014年 | 771篇 |
2013年 | 995篇 |
2012年 | 1565篇 |
2011年 | 1589篇 |
2010年 | 824篇 |
2009年 | 787篇 |
2008年 | 1294篇 |
2007年 | 1278篇 |
2006年 | 1242篇 |
2005年 | 1235篇 |
2004年 | 1061篇 |
2003年 | 1023篇 |
2002年 | 932篇 |
2001年 | 93篇 |
2000年 | 83篇 |
1999年 | 139篇 |
1998年 | 165篇 |
1997年 | 153篇 |
1996年 | 140篇 |
1995年 | 112篇 |
1994年 | 82篇 |
1993年 | 94篇 |
1992年 | 65篇 |
1991年 | 40篇 |
1990年 | 39篇 |
1989年 | 45篇 |
1988年 | 26篇 |
1987年 | 23篇 |
1986年 | 34篇 |
1985年 | 35篇 |
1984年 | 32篇 |
1983年 | 30篇 |
1982年 | 30篇 |
1981年 | 33篇 |
1980年 | 34篇 |
1979年 | 17篇 |
1978年 | 15篇 |
1976年 | 12篇 |
1975年 | 9篇 |
1974年 | 11篇 |
1973年 | 11篇 |
排序方式: 共有10000条查询结果,搜索用时 46 毫秒
991.
Yolanda Ruano Manuela Mollejo Teresa Ribalta Concepción Fiaño Francisca I Camacho Elena Gómez Angel Rodríguez de Lope Jose-Luis Hernández-Moneo Pedro Martínez Bárbara Meléndez 《Molecular cancer》2006,5(1):39-12
Background
Conventional cytogenetic and comparative genomic hybridization (CGH) studies in brain malignancies have shown that glioblastoma multiforme (GBM) is characterized by complex structural and numerical alterations. However, the limited resolution of these techniques has precluded the precise identification of detailed specific gene copy number alterations. 相似文献992.
Teresa Sampedro Gimeno Fernando Moreno Antón Sara López-Tarruella Cobo José Luis González Larriba Vicente Furio Bacete Eduardo Díaz-Rubio García 《Clinical & translational oncology》2006,8(1):57-59
Malignant melanoma is the most rapidly increasing cancer in the world. Metastatic disease occurs in 20% of patients, and prognosis
in these cases is poor. We report the case of a woman who presented breast metastasis as the first sign of recurrence of a
melanoma. 相似文献
993.
Carlos Conill Sandra Jorcano Josep Domingo-Doménech Rosa Gallego Josep Malvehy Susana Puig Marcelo Sánchez Ramón Vilella Teresa Castel 《Clinical & translational oncology》2006,8(4):266-270
Introduction Whole brain irradiation (WBRT) remains a recommended treatment for patients with brain metastases from malignant melanoma
in terms of symptom palliation, especially when extracranial systemic disease is present. Temozolomide (TMZ) has shown efficacy
in the treatment of metastatic melanoma. The objective was to evaluate the potential benefit in survival of two different
schedules of total dose and fractionation (20 Gy/5 fractions vs 30 Gy/10 fractions) and further TMZ based chemotherapy.
Materials and method We have conducted a retrospective study in a group of twenty-one patients (RTOG Recursive Partitioning Analysis class II)
of the use of WBRT with 20 Gy/5 fractions (n=11) and 30 Gy/10 fractions (n=10). All patients received further TMZ based chemotherapy
administered as a single chemotherapeutic agent or in combination with chemo-immunotherapy.
Results Prognostic variables such as: age, Karnofsky performance status, extracranial metastases and number of brain metastases, were
analyzed in both groups of treatment without statistically significant differences. The median survival time (MST) for WBRT
20 Gy group was 4 months (CI 95%: range 2–6 months) and for WBRT 30 Gy group was 4 months (CI 95%: range 0–7 months) without
statistically significant differences (Log rank p=0.74). There was one complete response and two partial responses.
Conclusions The results suggest that MST was not significantly affected by the total dose/fractionation schedule. 相似文献
994.
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. 总被引:27,自引:0,他引:27
Thomas E Witzig Ian W Flinn Leo I Gordon Christos Emmanouilides Myron S Czuczman Mansoor N Saleh Larry Cripe Gregory Wiseman Teresa Olejnik Pratik S Multani Christine A White 《Journal of clinical oncology》2002,20(15):3262-3269
PURPOSE: Rituximab is commonly used as a single agent or in combination therapy for non-Hodgkin's lymphoma (NHL). Ibritumomab tiuxetan radioimmunotherapy targets the same antigen as rituximab and has demonstrated efficacy in rituximab-na?ve NHL. This study evaluated ibritumomab tiuxetan in the treatment of rituximab-refractory follicular NHL. PATIENTS AND METHODS: Eligible patients were refractory to rituximab; this was defined as no objective response to rituximab (375 mg/m(2) weekly for 4 weeks) or time to progression (TTP) of < or = 6 months. The ibritumomab tiuxetan treatment regimen consisted of pretreatment with rituximab (250 mg/m(2) intravenously on days 1 and 8) to deplete peripheral blood B cells, then yttrium-90 ibritumomab tiuxetan (0.4 mCi/kg; maximum, 32 mCi) intravenously on day 8, administered on an outpatient basis. An imaging/dosimetry dose of indium-111 ibritumomab tiuxetan (5 mCi) was injected after rituximab (day 1) in 28 patients. RESULTS: Fifty-seven patients were treated. The median age was 54 years, 74% had tumors > or = 5 cm, and all were extensively pretreated (median, four prior therapies; range, one to nine). The estimated radiation-absorbed doses to healthy organs were below the study-defined limit in all patients studied with dosimetry. The overall response rate for the 54 patients with follicular NHL was 74% (15% complete responses and 59% partial responses). The Kaplan-Meier-estimated TTP was 6.8 months (range, 1.1 to > or = 25.9 months) for all patients and 8.7 months for responders. Adverse events were primarily hematologic; the incidence of grade 4 neutropenia, thrombocytopenia, and anemia was 35%, 9%, and 4%, respectively. CONCLUSION: Ibritumomab tiuxetan radioimmunotherapy is effective in rituximab-refractory patients. The only significant toxicity is hematologic. 相似文献
995.
Marta Salido Francesc Solé Ignasi Tusquets Josep M. Corominas Blanca Espinet MaLluïsa Mariñoso Teresa Baró MaCarmen Vela Xavier Fabregat Sergi Serrano 《Clinical & translational oncology》2002,4(5):255-259
The HER2/neu protooncogene is expressed in the breast, ovarian, gastric and prostatic tumors. Studies done in a number of laboratories have demostrated that 25%–30% of breast cancer contain overexpression of HER2/neu gene. A comparative analysis of the amplification and overexpression of HER2/neu using fluorescencein situ hybridization (FISH) and immunohistochemistry (IHC) was performed to determine the correlation between both techniques. In this study, FISH with HER2/neu probe (Path Vysion) is compared to immunohistochemistry (rabbit anti-human c-erbB-2-DAKO) in a series of 101 prospective human breast cancer specimens. Among 25 patients with score of IHC 3+, 23 (92%) were detected amplified by FISH and in two cases we found overexpression (3+) but without gene amplification. Out of 46 cases with 2+ by IHC, we found 43 not amplified, two moderately amplified (<10 copies) and one highly amplified (>10 copies) (6.5%). No patient with IHC O or 1+, presented amplification of HER2/neu. A good correlation between both techniques was found. FISH technique should have clinical utillity overoat in cases with 2+. 相似文献
996.
嘈杂语噪声下汉语整句识别的同质性研究 总被引:6,自引:0,他引:6
目的 获得嘈杂语噪声背景下汉语短句识别率一信噪比(Performance-Intensity,P-I)函数的斜率和50%的得分所对应的信噪比(记为SNR50),并对所有短句的同质性进行评估和调整.方法 采用16张(每张20句)新编嘈杂语噪声下汉语普通话短句识别表作为测试材料.选取年龄为21~25岁之间、听力/言语发育正常且日常以汉语普通话为交流方式的48名受试者按"随机区组设计"在-1、-4、-7、-10 dB四种信噪比条件下进行言语识别率的心理声学测量.使用Statistica7.0软件进行P-I函数拟合和统计分析.结果 320句语句在嘈杂语噪声下的言语识别P-I函数曲线的阈值呈正态分布,斜率呈不规则分布.剔除P-I函数强健性增长(斜率>55%/dB)的语句,并保留阈值变异度在±2σ内的语句,精选出同质性良好的240句.结论 逐个调整每句的SNR以实现同质性,可为编制"等言语识别阈级"的句表奠定扎实的心理声学基础. 相似文献
997.
OBJECTIVE: To determine if exposure to a second language impacts the ability of children with cochlear implants to develop spoken English skills. STUDY DESIGN: Matched-pairs comparison of postoperative speech perception and speech/language data of children from monolingual and bilingual homes with cochlear implants. SETTING: Tertiary medical facility. SUBJECTS: Twelve matched pairs of children with unilateral cochlear implants who reside in monolingual or in bilingual homes. Pairs were matched for age of implantation, cochlear anatomy, educational setting, and device type. All subjects received their implant before the age of 6 years. INTERVENTION: Subjects participated in routine speech perception and speech and language assessments at various postimplantation time intervals. MAIN OUTCOME MEASURES: Matched-pairs t tests and mixed-model analyses were used to evaluate and compare scores obtained by the 2 groups on the Peabody Picture Vocabulary Test, The MacArthur-Bates Communicative Development Inventory: Words and Gestures, The Oral and Written Language Scales, The Infant-Toddler Meaningful Auditory Integration Scale, and the Student Oral Language Observation Matrix. RESULTS: No significant differences were found between the scores of children living in bilingual homes when compared with the scores obtained by children living in monolingual homes at any interval tested. CONCLUSION: This study supports the belief that exposure to a second language at home does not impair primary language acquisition for some young children with cochlear implants. The study suggests that some children with cochlear implants can learn multiple spoken languages and that parents of such children do not need to avoid using a minority language with their child who has a cochlear implant. 相似文献
998.
Christian Hampp BS Abraham G. Hartzema PharmD MSPH PhD FISPE Teresa L. Kauf PhD 《Value in health》2008,11(3):389-399
Objective: To estimate the incremental cost-utility ratio (ICUR) of rimonabant 20 mg/day in the treatment of obesity from a third-party payer's perspective.
Methods: Pooled data from three randomized clinical trials were used to develop a decision tree with five treatment alternatives: 1- and 2-year treatment with rimonabant, 2-year placebo, 1-year rimonabant followed by 1-year placebo, and no treatment. All alternatives, except no treatment, were accompanied by lifestyle interventions. Treatment benefits included gains in quality-adjusted life-years (QALYs) and reduced incidence of type-2 diabetes mellitus and coronary heart disease (CHD). Drug acquisition cost was based on the average wholesale price of a comparator drug minus 15%. One-way and probabilistic sensitivity analyses were conducted to assess the stability of the base-case results.
Results: One-year rimonabant and 1-year rimonabant followed by placebo were extendedly dominated. Rimonabant for 2 years showed an average weight reduction of 8.49 kg, a body mass index reduction of 2.98 kg/m2 and reduced waist circumference by 8.24 cm (placebo: 3.55 kg, 1.22 kg/m2 , 4.18 cm). Two-year rimonabant was associated with a relative reduction in the 5-year incidence of CHD by 7.15% and of diabetes by 9.28%. Incremental benefits (costs) were 0.0984 QALYs ($5209) compared to no treatment and 0.0581 QALYs ($4182) compared to placebo, producing ICURs of $52,936/QALY (95% confidence interval $39K–$69K) and $71,973/QALY ($51K–$98K), respectively.
Conclusions: Rimonabant combined with lifestyle interventions has the potential to decrease the rate of obesity-related comorbidities and improve health-related quality of life, albeit at considerable cost. 相似文献
Methods: Pooled data from three randomized clinical trials were used to develop a decision tree with five treatment alternatives: 1- and 2-year treatment with rimonabant, 2-year placebo, 1-year rimonabant followed by 1-year placebo, and no treatment. All alternatives, except no treatment, were accompanied by lifestyle interventions. Treatment benefits included gains in quality-adjusted life-years (QALYs) and reduced incidence of type-2 diabetes mellitus and coronary heart disease (CHD). Drug acquisition cost was based on the average wholesale price of a comparator drug minus 15%. One-way and probabilistic sensitivity analyses were conducted to assess the stability of the base-case results.
Results: One-year rimonabant and 1-year rimonabant followed by placebo were extendedly dominated. Rimonabant for 2 years showed an average weight reduction of 8.49 kg, a body mass index reduction of 2.98 kg/m
Conclusions: Rimonabant combined with lifestyle interventions has the potential to decrease the rate of obesity-related comorbidities and improve health-related quality of life, albeit at considerable cost. 相似文献
999.
Anouk T Dev Teresa L Kauf Amany Zekry Keyur Patel Karen Heller Kevin A Schulman John G McHutchison 《BMC health services research》2008,8(1):208
Background
Although clinical research is integral to the advancement of medical knowledge, physicians face a variety of obstacles to their participation as investigators in clinical trials. We examined factors that influence the participation of gastroenterologists and hepatologists in clinical research. 相似文献1000.
The relationship of socioeconomic indicators (education, occupation and residence) to short-term all cause mortality and coronary heart disease (CHD) mortality was evaluated in an Italian population sample. Socioeconomic indicators (education, occupational level and residence) and major CHD risk factors were measured in 12,361 males aged 40–69 years; mortality data by cause were collected for the next 6 years. All cause and CHD mortality risk ratio (RR) in the different educational and occupational levels and residence were computed by Cox proportional hazards models. After 6 years 385 men died, of whom 105 were coronary fatalities. No association with educational level was found for all cause mortality (RR: 1.00 high, 0.71 medium, 0.77 low) and for CHD mortality (RR: 1.00 high, 0.39 intermediate, 0.71 low). Occupational level was significantly associated (p < 0.031) with all cause mortality (RR: 1.00 high-intermediate, 1.27 low). Urban vs. rural residence (RR: 1.00) showed a RR for all cause mortality of 1.33 (p < 0.011). Adjustment for bio-behavioral risk factors did not change the above results; only mortality for CHD of urban vs. rural residents increased (RR: 1.94, p = 0.004). In conclusion the negative association of mortality with occupational level, albeit not with education, indicates that occupation is a better indicator of socioeconomic status in Italy. Status incongruity as well as residence in an urban environment could be risk conditions for total and CHD mortality. 相似文献